PharmaCyte Biotech, Inc. PMCB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
4/9
Piotroski F — financial health
13.39
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | $30.7M | — | — | $51.9M |
| 2024 | $0 | $333,763 | — | — | $27.6M |
| 2023 | $0 | -$4.3M | — | — | $72.7M |
| 2022 | $0 | -$4.2M | — | — | $89.9M |
| 2021 | $0 | -$3.6M | — | — | $6.7M |
| 2020 | $0 | -$3.8M | — | — | $5.1M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 13.39 (safe)
- Working capital / assets 0.353
- Retained earnings / assets -1.54
- EBIT / assets -0.079
- Equity / liabilities 15.834
Source: SEC EDGAR filings · CIK 0001157075 · as of 2025-04-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.